180 related articles for article (PubMed ID: 38096371)
21. Epigenetic regulation of protein translation in KMT2A-rearranged AML.
Lenard A; Xie HM; Pastuer T; Shank T; Libbrecht C; Kingsley M; Riedel SS; Yuan ZF; Zhu N; Neff T; Bernt KM
Exp Hematol; 2020 May; 85():57-69. PubMed ID: 32437908
[TBL] [Abstract][Full Text] [Related]
22. Menin is necessary for long term maintenance of meningioma-1 driven leukemia.
Libbrecht C; Xie HM; Kingsley MC; Haladyna JN; Riedel SS; Alikarami F; Lenard A; McGeehan GM; Ernst P; Bernt KM
Leukemia; 2021 May; 35(5):1405-1417. PubMed ID: 33542482
[TBL] [Abstract][Full Text] [Related]
23. A Box of Chemistry to Inhibit the MEN1 Tumor Suppressor Gene Promoting Leukemia.
Ozyerli-Goknar E; Nizamuddin S; Timmers HTM
ChemMedChem; 2021 May; 16(9):1391-1402. PubMed ID: 33534953
[TBL] [Abstract][Full Text] [Related]
24. Therapeutic implications of menin inhibition in acute leukemias.
Issa GC; Ravandi F; DiNardo CD; Jabbour E; Kantarjian HM; Andreeff M
Leukemia; 2021 Sep; 35(9):2482-2495. PubMed ID: 34131281
[TBL] [Abstract][Full Text] [Related]
25. SET-PP2A complex as a new therapeutic target in KMT2A (MLL) rearranged AML.
Di Mambro A; Arroyo-Berdugo Y; Fioretti T; Randles M; Cozzuto L; Rajeeve V; Cevenini A; Austin MJ; Esposito G; Ponomarenko J; Lucas CM; Cutillas P; Gribben J; Williams O; Calle Y; Patel B; Esposito MT
Oncogene; 2023 Dec; 42(50):3670-3683. PubMed ID: 37891368
[TBL] [Abstract][Full Text] [Related]
26. A 2024 Update on Menin Inhibitors. A New Class of Target Agents against KMT2A-Rearranged and NPM1-Mutated Acute Myeloid Leukemia.
Candoni A; Coppola G
Hematol Rep; 2024 Apr; 16(2):244-254. PubMed ID: 38651453
[TBL] [Abstract][Full Text] [Related]
27. Targeting the undruggable: menin inhibitors ante portas.
Dempke WCM; Desole M; Chiusolo P; Sica S; Schmidt-Hieber M
J Cancer Res Clin Oncol; 2023 Sep; 149(11):9451-9459. PubMed ID: 37103568
[TBL] [Abstract][Full Text] [Related]
28. A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged Leukemia.
Krivtsov AV; Evans K; Gadrey JY; Eschle BK; Hatton C; Uckelmann HJ; Ross KN; Perner F; Olsen SN; Pritchard T; McDermott L; Jones CD; Jing D; Braytee A; Chacon D; Earley E; McKeever BM; Claremon D; Gifford AJ; Lee HJ; Teicher BA; Pimanda JE; Beck D; Perry JA; Smith MA; McGeehan GM; Lock RB; Armstrong SA
Cancer Cell; 2019 Dec; 36(6):660-673.e11. PubMed ID: 31821784
[TBL] [Abstract][Full Text] [Related]
29. The future of HOXA- expressing leukemias: Menin inhibitor response and resistance.
Wenge DV; Armstrong SA
Curr Opin Hematol; 2024 Mar; 31(2):64-70. PubMed ID: 38010951
[TBL] [Abstract][Full Text] [Related]
30. HOXBLINC long non-coding RNA activation promotes leukemogenesis in NPM1-mutant acute myeloid leukemia.
Zhu G; Luo H; Feng Y; Guryanova OA; Xu J; Chen S; Lai Q; Sharma A; Xu B; Zhao Z; Feng R; Ni H; Claxton D; Guo Y; Mesa RA; Qiu Y; Yang FC; Li W; Nimer SD; Huang S; Xu M
Nat Commun; 2021 Mar; 12(1):1956. PubMed ID: 33782403
[TBL] [Abstract][Full Text] [Related]
31. Menin inhibitor MI-3454 induces remission in MLL1-rearranged and NPM1-mutated models of leukemia.
Klossowski S; Miao H; Kempinska K; Wu T; Purohit T; Kim E; Linhares BM; Chen D; Jih G; Perkey E; Huang H; He M; Wen B; Wang Y; Yu K; Lee SC; Danet-Desnoyers G; Trotman W; Kandarpa M; Cotton A; Abdel-Wahab O; Lei H; Dou Y; Guzman M; Peterson L; Gruber T; Choi S; Sun D; Ren P; Li LS; Liu Y; Burrows F; Maillard I; Cierpicki T; Grembecka J
J Clin Invest; 2020 Feb; 130(2):981-997. PubMed ID: 31855575
[TBL] [Abstract][Full Text] [Related]
32. Imidazoquinoxaline derivative EAPB0503: A promising drug targeting mutant nucleophosmin 1 in acute myeloid leukemia.
Nabbouh AI; Hleihel RS; Saliba JL; Karam MM; Hamie MH; Wu HJM; Berthier CP; Tawil NM; Bonnet PA; Deleuze-Masquefa C; El Hajj HA
Cancer; 2017 May; 123(9):1662-1673. PubMed ID: 28055106
[TBL] [Abstract][Full Text] [Related]
33. The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia.
Issa GC; Aldoss I; DiPersio J; Cuglievan B; Stone R; Arellano M; Thirman MJ; Patel MR; Dickens DS; Shenoy S; Shukla N; Kantarjian H; Armstrong SA; Perner F; Perry JA; Rosen G; Bagley RG; Meyers ML; Ordentlich P; Gu Y; Kumar V; Smith S; McGeehan GM; Stein EM
Nature; 2023 Mar; 615(7954):920-924. PubMed ID: 36922593
[TBL] [Abstract][Full Text] [Related]
34. Potent preclinical activity of FLT3-directed chimeric antigen receptor T-cell immunotherapy against
Niswander LM; Graff ZT; Chien CD; Chukinas JA; Meadows CA; Leach LC; Loftus JP; Kohler ME; Tasian SK; Fry TJ
Haematologica; 2023 Feb; 108(2):457-471. PubMed ID: 35950535
[TBL] [Abstract][Full Text] [Related]
35. KMT2A-rearranged infantile acute myeloid leukemia masquerading as juvenile myelomonocytic leukemia.
Kanayama T; Imamura T; Kawabe Y; Osone S; Tahara J; Iwasaki F; Miyagawa N; Goto H; Imashuku S; Hosoi H
Int J Hematol; 2018 Dec; 108(6):665-669. PubMed ID: 30143999
[TBL] [Abstract][Full Text] [Related]
36. The Menin story in acute myeloid leukaemia-The road to success.
Kühn MWM; Ganser A
Br J Haematol; 2024 May; ():. PubMed ID: 38710595
[TBL] [Abstract][Full Text] [Related]
37. Hematopoietic stem cell transplantation for pediatric acute myeloid leukemia patients with KMT2A rearrangement; A nationwide retrospective analysis in Japan.
Miyamura T; Kudo K; Tabuchi K; Ishida H; Tomizawa D; Adachi S; Goto H; Yoshida N; Inoue M; Koh K; Sasahara Y; Fujita N; Kakuda H; Noguchi M; Hiwatari M; Hashii Y; Kato K; Atsuta Y; Okamoto Y
Leuk Res; 2019 Dec; 87():106263. PubMed ID: 31707119
[TBL] [Abstract][Full Text] [Related]
38. Functional diversity of inhibitors tackling the differentiation blockage of MLL-rearranged leukemia.
Brzezinka K; Nevedomskaya E; Lesche R; Steckel M; Eheim AL; Haegebarth A; Stresemann C
J Hematol Oncol; 2019 Jun; 12(1):66. PubMed ID: 31253180
[TBL] [Abstract][Full Text] [Related]
39. Menin-MLL protein-protein interaction inhibitors: a patent review (2014-2021).
Bai H; Zhang SQ; Lei H; Wang F; Ma M; Xin M
Expert Opin Ther Pat; 2022 May; 32(5):507-522. PubMed ID: 35202550
[TBL] [Abstract][Full Text] [Related]
40. Novel Compounds Synergize With Venetoclax to Target KMT2A-Rearranged Pediatric Acute Myeloid Leukemia.
Tregnago C; Benetton M; Da Ros A; Borella G; Longo G; Polato K; Francescato S; Biffi A; Pigazzi M
Front Pharmacol; 2021; 12():820191. PubMed ID: 35153769
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
